Friday, 20 Apr 2018

You are here

The RheumNow Week in Review – 25 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on IL-1 and pregnancy, contraceptives and the risk of RA, Calprotectin the biomarker, T2T failing, and the loss of a giant in rheumatology.

  1. Data on IL-1 inhibitors and pregnancy: 11 paternal & 31 maternal (23 Anakinra, 8 Cannakinumab) exposures, mosly live births and only  1 renal agenesis/ectopic neurohypophysis.  https://buff.ly/2wstyyA
  2. 435 Nordic JIA pts, Uveitis found in 20.5%; 90% asympt. Predictors of uveitis were ANA+, AHA+, JIA onset <7yrs in girls, not boys  https://buff.ly/2ise342
  3. Study of 215 RA patients Rx with DMARDs & T2T strategy. Serum Calprotectin shown to be strong biomarker; significantly correlated with ESR, CDAI, US Power doppler, Xray progression https://t.co/82YvTFtcAV
  4. 4666 elderly Canadian RA patients, only 59% were deemed to be adherent to biologic therapy, Nonadherent used more steroids https://t.co/kmEmgmmc4p
  5. 55% Americans take prescription medicine; now more than ever. https://t.co/3ytMXHHhVP
  6. Swedish EIRA study: Oral contraceptive use decreases risk of ACPA+ RA. breast feeding has no effect. Ever/past oral contraceptive users have a decreased risk of ACPA-positive RA (OR=0.84) https://t.co/7p9wpfHBJY
  7. Ironwood announces FDA approval of its combo drug lesinurad/allopurinol (Duzallo) in a 200/300 tablet. Could this be useful? https://t.co/lcUZTieKqg
  8. 30 yoF with non itchy, nonpainful palpable purpura lesions on legs & abdomen on/off for last 8 mos. Patient has Hx of HBV Rx with Tenovir. What would you do next?
  9. Leukocytoclastic vasculitis is most commonly caused by antibiotic use (Cipro, Cefazolin ) https://t.co/I893XN737C
  10. Non-Tuberculous Mycobacterial Infections - Diagnosis and Management for the Rheumatologist
  11. IV Golimumab Shines in Psoriatic Arthritis  
  12. Treat-to-Target a Bust with Rheumatologists   
  13. It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk 
  14. Dr. H. Ralph Schumacher (1933-2017) 
  15. Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.